Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.
Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.
The personal genetics company created a therapeutics group to extricate new drug targets from its research database.
A research collaboration between medical centers, drugmaker Biogen Idec and a biotechnology institute have identified a gene that could lead to new drug targets for sporadic amyotrophic lateral sclerosis—or Lou Gehrig's disease.
The biotech exec speaks about the global launch of his firm's lead product, Duchenne drug Translarna.
Canadian firm presents FDA with its third biosimilar application.
The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million
Allergan inches closer to Valeant takeover; Mylan trials underway for Lantus biosimilar and generic Advair; FDA advisers to make decision tomorrow on whether testosterone products are being prescribed correctly and if the drugs' label merits change.
Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen.
- Five things for pharma marketers to know: Friday, February 24, 2017
- MAHF honors Abbate and Lazur, Future Famers
- Five things for pharma marketers to know: Thursday, February 23, 2017
- Almost one-third of programmatic ads violate IAB guidelines, study finds
- Why Pharma Refuses to See Value in 'Influence'